Actinium Capital Stock vs Retained Earnings Analysis

ATNM Stock

USD 7.41 0.00 0.00%

Actinium Pharmaceuticals financial indicator trend analysis is way more than just evaluating Actinium Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Actinium Pharmaceuticals is a good investment. Please check the relationship between Actinium Pharmaceuticals Capital Stock and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.

Capital Stock vs Retained Earnings

Capital Stock vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Actinium Pharmaceuticals Capital Stock account and Retained Earnings. At this time, the significance of the direction appears to have strong relationship.

The correlation between Actinium Pharmaceuticals' Capital Stock and Retained Earnings is 0.69. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Actinium Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Actinium Pharmaceuticals' Capital Stock and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Actinium Pharmaceuticals are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Capital Stock i.e., Actinium Pharmaceuticals' Capital Stock and Retained Earnings go up and down completely randomly.

Correlation Coefficient

0.69

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capital Stock

The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Actinium Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Actinium Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.At this time, Actinium Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 29th of April 2024, Issuance Of Capital Stock is likely to grow to about 24.8 M, while Enterprise Value Over EBITDA is likely to drop (1.24).

Actinium Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Other Current Assets	Property Plant And Equipment Gross	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Retained Earnings Total Equity
Total Assets		0.79	-0.75	0.52	0.86	-1.0	-0.87	0.85	1.0	1.0	-0.51	0.95	0.78	0.91	0.8	1.0	-0.46	0.85	0.75	0.84	0.82	0.83	0.5	0.83	0.96	-0.85
Short Long Term Debt Total	0.79		-0.89	0.49	0.44	-0.76	-0.81	0.84	0.78	0.78	-0.23	0.84	0.92	0.79	0.93	0.78	-0.16	0.98	0.87	0.98	0.57	0.96	0.72	0.96	0.71	-0.72
Other Current Liab	-0.75	-0.89		-0.34	-0.36	0.72	0.65	-0.74	-0.74	-0.74	0.33	-0.8	-0.98	-0.65	-0.96	-0.74	0.26	-0.92	-0.96	-0.89	-0.48	-0.94	-0.39	-0.92	-0.68	0.52
Total Current Liabilities	0.52	0.49	-0.34		0.41	-0.53	-0.58	0.59	0.52	0.52	-0.27	0.46	0.43	0.55	0.54	0.52	-0.27	0.46	0.4	0.45	0.53	0.46	0.43	0.43	0.39	-0.46
Total Stockholder Equity	0.86	0.44	-0.36	0.41		-0.89	-0.69	0.63	0.87	0.87	-0.46	0.71	0.37	0.75	0.4	0.87	-0.47	0.51	0.34	0.51	0.83	0.46	0.4	0.47	0.83	-0.78
Net Debt	-1.0	-0.76	0.72	-0.53	-0.89		0.85	-0.83	-1.0	-1.0	0.51	-0.93	-0.75	-0.9	-0.77	-1.0	0.47	-0.82	-0.72	-0.81	-0.83	-0.8	-0.48	-0.8	-0.95	0.84
Retained Earnings	-0.87	-0.81	0.65	-0.58	-0.69	0.85		-0.94	-0.86	-0.86	0.31	-0.89	-0.72	-0.99	-0.76	-0.86	0.26	-0.84	-0.66	-0.87	-0.76	-0.81	-0.66	-0.83	-0.88	0.95
Accounts Payable	0.85	0.84	-0.74	0.59	0.63	-0.83	-0.94		0.84	0.84	-0.27	0.85	0.78	0.92	0.81	0.84	-0.22	0.84	0.69	0.87	0.76	0.83	0.58	0.82	0.8	-0.91
Cash	1.0	0.78	-0.74	0.52	0.87	-1.0	-0.86	0.84		1.0	-0.51	0.94	0.77	0.91	0.79	1.0	-0.46	0.85	0.75	0.83	0.82	0.82	0.49	0.82	0.96	-0.84
Cash And Short Term Investments	1.0	0.78	-0.74	0.52	0.87	-1.0	-0.86	0.84	1.0		-0.51	0.94	0.77	0.91	0.79	1.0	-0.46	0.85	0.75	0.83	0.82	0.82	0.49	0.82	0.96	-0.84
Common Stock Total Equity	-0.51	-0.23	0.33	-0.27	-0.46	0.51	0.31	-0.27	-0.51	-0.51		-0.45	-0.35	-0.3	-0.36	-0.51	0.99	-0.33	-0.37	-0.29	-0.46	-0.32	-0.04	-0.33	-0.52	0.29
Common Stock Shares Outstanding	0.95	0.84	-0.8	0.46	0.71	-0.93	-0.89	0.85	0.94	0.94	-0.45		0.86	0.92	0.87	0.94	-0.38	0.92	0.85	0.9	0.72	0.92	0.54	0.92	0.95	-0.84
Non Current Liabilities Total	0.78	0.92	-0.98	0.43	0.37	-0.75	-0.72	0.78	0.77	0.77	-0.35	0.86		0.72	0.99	0.77	-0.27	0.95	0.99	0.92	0.5	0.97	0.45	0.96	0.73	-0.58
Other Stockholder Equity	0.91	0.79	-0.65	0.55	0.75	-0.9	-0.99	0.92	0.91	0.91	-0.3	0.92	0.72		0.75	0.91	-0.24	0.84	0.67	0.86	0.78	0.81	0.61	0.83	0.92	-0.95
Total Liab	0.8	0.93	-0.96	0.54	0.4	-0.77	-0.76	0.81	0.79	0.79	-0.36	0.87	0.99	0.75		0.79	-0.29	0.95	0.97	0.93	0.53	0.97	0.47	0.95	0.74	-0.61
Total Current Assets	1.0	0.78	-0.74	0.52	0.87	-1.0	-0.86	0.84	1.0	1.0	-0.51	0.94	0.77	0.91	0.79		-0.46	0.84	0.74	0.83	0.82	0.82	0.49	0.82	0.96	-0.85
Common Stock	-0.46	-0.16	0.26	-0.27	-0.47	0.47	0.26	-0.22	-0.46	-0.46	0.99	-0.38	-0.27	-0.24	-0.29	-0.46		-0.25	-0.29	-0.22	-0.45	-0.24	-0.02	-0.25	-0.47	0.24
Property Plant And Equipment Net	0.85	0.98	-0.92	0.46	0.51	-0.82	-0.84	0.84	0.85	0.85	-0.33	0.92	0.95	0.84	0.95	0.84	-0.25		0.92	0.99	0.6	0.98	0.66	1.0	0.82	-0.75
Current Deferred Revenue	0.75	0.87	-0.96	0.4	0.34	-0.72	-0.66	0.69	0.75	0.75	-0.37	0.85	0.99	0.67	0.97	0.74	-0.29	0.92		0.88	0.44	0.96	0.4	0.94	0.72	-0.5
Non Current Assets Total	0.84	0.98	-0.89	0.45	0.51	-0.81	-0.87	0.87	0.83	0.83	-0.29	0.9	0.92	0.86	0.93	0.83	-0.22	0.99	0.88		0.59	0.96	0.67	0.98	0.8	-0.79
Other Current Assets	0.82	0.57	-0.48	0.53	0.83	-0.83	-0.76	0.76	0.82	0.82	-0.46	0.72	0.5	0.78	0.53	0.82	-0.45	0.6	0.44	0.59		0.58	0.58	0.57	0.79	-0.78
Property Plant And Equipment Gross	0.83	0.96	-0.94	0.46	0.46	-0.8	-0.81	0.83	0.82	0.82	-0.32	0.92	0.97	0.81	0.97	0.82	-0.24	0.98	0.96	0.96	0.58		0.59	0.99	0.79	-0.7
Short Term Debt	0.5	0.72	-0.39	0.43	0.4	-0.48	-0.66	0.58	0.49	0.49	-0.04	0.54	0.45	0.61	0.47	0.49	-0.02	0.66	0.4	0.67	0.58	0.59		0.63	0.47	-0.65
Property Plant Equipment	0.83	0.96	-0.92	0.43	0.47	-0.8	-0.83	0.82	0.82	0.82	-0.33	0.92	0.96	0.83	0.95	0.82	-0.25	1.0	0.94	0.98	0.57	0.99	0.63		0.81	-0.72
Net Tangible Assets	0.96	0.71	-0.68	0.39	0.83	-0.95	-0.88	0.8	0.96	0.96	-0.52	0.95	0.73	0.92	0.74	0.96	-0.47	0.82	0.72	0.8	0.79	0.79	0.47	0.81		-0.85
Retained Earnings Total Equity	-0.85	-0.72	0.52	-0.46	-0.78	0.84	0.95	-0.91	-0.84	-0.84	0.29	-0.84	-0.58	-0.95	-0.61	-0.85	0.24	-0.75	-0.5	-0.79	-0.78	-0.7	-0.65	-0.72	-0.85

Click cells to compare fundamentals

Actinium Pharmaceuticals Account Relationship Matchups

Actinium Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.7M	66.4M	80.4M	114.2M	81.4M	85.5M
Short Long Term Debt Total	1.4M	738K	310K	2.6M	2.1M	2.2M
Other Current Liab	4.6M	4.3M	6.5M	(35M)	(31.5M)	(29.9M)
Total Current Liabilities	5.3M	4.8M	6.8M	10.6M	8.5M	4.7M
Total Stockholder Equity	5.6M	61.3M	73.5M	66.5M	36.4M	18.5M
Net Debt	(7.8M)	(62.8M)	(77.5M)	(106.3M)	(74.6M)	(70.8M)
Retained Earnings	(208.8M)	(231.0M)	(255.7M)	(288.8M)	(337.6M)	(320.7M)
Accounts Payable	4.6M	4.3M	5.5M	10.1M	8.0M	8.4M
Cash	9.3M	63.6M	77.8M	108.9M	76.7M	80.5M
Cash And Short Term Investments	9.3M	63.6M	77.8M	108.9M	76.7M	80.5M
Common Stock Total Equity	115.7K	164.7K	18K	22K	25.3K	24.0K
Common Stock Shares Outstanding	5.0M	12.1M	20.6M	24.1M	26.6M	27.9M
Liabilities And Stockholders Equity	11.7M	66.4M	80.4M	114.2M	81.4M	85.5M
Non Current Liabilities Total	682.3K	311K	3K	37.1M	36.6M	38.4M
Other Stockholder Equity	214.2M	292.3M	329.3M	355.2M	373.9M	392.6M
Total Liab	6.0M	5.1M	6.8M	47.7M	45.1M	47.3M
Total Current Assets	10.1M	64.9M	79.7M	110.9M	78.3M	82.2M
Common Stock	164.7K	18K	22K	26K	28K	54.5K
Property Plant And Equipment Net	1.1M	1.0M	639K	2.9M	2.9M	3.0M
Current Deferred Revenue	(4.6M)	(4.3M)	998K	35M	40.3M	42.3M
Non Current Assets Total	1.6M	1.5M	639K	3.3M	3.2M	3.3M
Other Current Assets	833.8K	1.4M	1.9M	2.0M	1.6M	1.2M
Property Plant And Equipment Gross	1.1M	312K	974K	3.4M	3.6M	3.7M
Short Term Debt	745.8K	427K	307K	498K	541K	360.4K
Property Plant Equipment	1.1M	1.0M	639K	2.9M	3.4M	3.6M
Net Tangible Assets	5.6M	61.3M	73.5M	66.5M	76.5M	80.3M
Retained Earnings Total Equity	(186.9M)	(208.8M)	(231.0M)	(255.7M)	(230.2M)	(241.7M)
Capital Surpluse	195.6M	214.2M	292.3M	329.3M	378.7M	201.8M
Non Currrent Assets Other	49.9K	50K	(639K)	302K	(1.0)	(0.95)
Other Assets	441.0K	441.2K	1.2M	302K	1.0	0.95
Net Invested Capital	6.0M	61.3M	73.5M	66.5M	36.4M	41.9M
Net Working Capital	4.7M	60.2M	72.9M	100.3M	69.8M	51.8M
Capital Lease Obligations	1.0M	738K	310K	2.6M	2.1M	1.2M
Capital Stock	164.7K	18K	22K	26K	28K	49.9K

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Actinium Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Actinium Pharmaceuticals' short interest history, or implied volatility extrapolated from Actinium Pharmaceuticals options trading.

Pair Trading with Actinium Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actinium Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actinium Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Actinium Stock

0.55	ETON	Eton Pharmaceuticals Upward Rally	Pair Corr
0.41	DVAX	Dynavax Technologies Financial Report 7th of May 2024	Pair Corr

The ability to find closely correlated positions to Actinium Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Actinium Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Actinium Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Actinium Pharmaceuticals to buy it.

The correlation of Actinium Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Actinium Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Actinium Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Actinium Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:

How To Invest In Actinium

Details

Is Actinium Stock a good investment?

Details

What is Actinium Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Actinium Stock analysis

When running Actinium Pharmaceuticals' price analysis, check to measure Actinium Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinium Pharmaceuticals is operating at the current time. Most of Actinium Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Actinium Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinium Pharmaceuticals' price. Additionally, you may evaluate how the addition of Actinium Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	CEOs Directory Screen CEOs from public companies around the world
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon

Is Actinium Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.83)

Revenue Per Share

0.003

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.33)

Return On Equity

(0.92)

The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Actinium Capital Stock vs Retained Earnings Analysis

Capital Stock vs Retained Earnings

Capital Stock vs Retained Earnings Correlation Analysis

Correlation Coefficient

Capital Stock

Retained Earnings

Actinium Pharmaceuticals fundamental ratios Correlations

Actinium Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Actinium Pharmaceuticals fundamental ratios Accounts

Pair Trading with Actinium Pharmaceuticals

Moving against Actinium Stock

Complementary Tools for Actinium Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Other Stockholder Equity	- 0.99	Retained Earnings
Non Current Liabilities Total	- 0.98	Other Current Liab